- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
I
Principal Investigator(s)
Jill Schwartz
Objective
To evaluate TFV/FTC and TFV only fast dissolve vaginal tablets.
Prevention Option(s)
Microbicides
Multipurpose Prevention Technologies
Study Design
Randomized
Double-blind
Arms and Assigned Interventions
Description
Vaginal tablet containing 40 mg of TFV
Mode of Delivery
Tablet
Products
1% tenofovir gel
ARMs
Experimental
Description
Emtricitabine (FTC) Alone Vaginal Tablet
Mode of Delivery
Tablet
Products
FTC
Description
Vaginal tablet with 40 mg TFV and 40 mg FTC
Mode of Delivery
Tablet
Products
TVF/FTC
ARMs
Experimental
Description
Vaginal Tablet containing no drug
Mode of Delivery
Tablet
ARMs
Placebo Comparator
Official Code
Trial Sponsors
CONRAD
February 2013
January 2014
Enrollment
48
18
Years
50
Years
Population
Women
Sites
Albert Einstein College of Medicine
Bronx, New York
United States of America
Eastern Virginia Medical School
Norfolk, Virginia
United States of America